Dr. Yaron Daniely has been the President and Chief Executive Officer and a Director of Alcobra Ltd, since March 2010. Immediately prior to joining Alcobra and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal delivery technologies based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was the General Manager of Gamida Cell—Teva Joint Venture Ltd., a joint venture company that acquired an exclusive license to develop and commercialize a Phase 3-stage cell therapy product for treatment of Leukemia and Lymphoma based in Jerusalem, Israel. From 2003-2007, Dr. Daniely also served as the Vice President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial transactions for the Company. In addition, he co-founded and served as a director of Bioblast Ltd. (NASADQ:ORPN). Dr. Daniely holds a B.Sc. degree in Biological Sciences from Florida International University, and holds a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine. Following his doctoral program, Dr. Daniely served as an NIH Visiting Fellow in its Cell Biology section and a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute of Technology. Dr. Daniely co-founded Israel’s first M.B.A. program specializing in Biomedical Management at the College of Management Academic Studies (Rishon Letzion, Israel) and has served as the program’s director since its inception.
Dr. Keynan joined Yissum in 2008, with a strong background in scientific, industrial & business strategy. She joined Yissum from RadBioMed, one of Israel's leading biomedical incubators, where as project manager she was responsible for the deal flow, evaluation and management assistance to the CEO. Prior to that she worked at Quark Pharma, one of Israel's top biopharmaceutical companies, where she was the metabolic cell-based bioassay manager. Dr. Keynan holds a Ph.D. in biochemistry from the Hebrew University Hadassah Medical School in Jerusalem, and spent four years as a postdoctoral fellow in the biochemistry and molecular biology department at Leeds University, UK.
Mr. Cohen was appointed as Yissum’s CFO at the end of 2010. Prior to that, he served as Yissum’s controller since 2006. Previous experience includes the Finance department of the Jewish Agency and KPMG Somekh Chaikin, accounting firm. Mr. Cohen is a certified public accountant (Israel) and holds a BA degree in Business Management and Accounting and MBA (Cum Laude), both from the Israeli College of Management.
Ms. Markel joined Yissum in October 2008 from ProChon Biotech, where she headed the business development activities initiating and establishing joint projects with major companies in the field of sports medicine, in addition to negotiating distribution deals in Europe. Prior to that she served as a marketing strategy consultant to Invitrogen Ltd., a global provider and producer of advanced tools for biological research. She established the US sales and marketing operations of QuantomiX, an Israeli company, initiating the adoption of a cutting edge innovative technology in the field of electron microscopy by over 70 leading global pharmaceutical and biotechnology companies and major universities. Earlier in her career, she was a sales executive at Beckman Coulter Inc., a world leader in the production of scientific and diagnostic instrumentation for the life science markets, consulting on robotic systems for drug discovery. Ariela holds a B.Sc. (cum laude) and M.Sc. in biophysical chemistry from Ben Gurion University and an MBA from the joint international programme of the Kellogg School of Management at Northwestern University and Tel Aviv University.
Dr. Goldwaser serves as VP, Head of Research Collaborations of Yissum & Business Development Manager of the Institute of Drug Research of the School of Pharmacy of the Hebrew University of Jerusalem (IDR). Dr. Goldwaser's career in the bio-pharmaceutical industry began over a decade ago, spanning executive and R&D management roles in the biotechnology, chemical and biological drug development markets. Dr. Goldwaser served as CEO of NasVax from its foundation in 2004 and later as president until April 2010. Dr. Goldwaser joined NasVax from Sol-Gel Technologies, where he served as CTO and Chief Biologist and R&D Project Manager overseeing the Company's experiments, worldwide collaborations, IP management, R&D and drug-candidate evaluation. Prior to that, Dr. Goldwaser worked as Lapid Pharmaceuticals' R&D Manager and Supervisor from 1999 through 2002. Dr. Goldwaser earned his Ph.D. degree in Biological Chemistry from the Weizmann Institute of Science, Rehovot, Israel, his M.Sc. in Medicinal Science from the Sackler School of Medicine, Tel Aviv, Israel, and a B.Sc. in Chemistry from the Hebrew University, Jerusalem, Israel. He is the co-owner of several registered patents of pharmacology and has authored numerous publications in this field.
Tamir Huberman joined Yissum in 2004, he is the Chief Information Officer and further responsible for the Marketing of Yissum. In addition, he is also the IT Director at ITTN; the Israeli Technology Transfer Organization, InnerEye and BriefCam. Prior to joining Yissum, Mr. Huberman was the co-founder of Artigon, served as part of the R&D team at Orgenics and as the Head of IP and R&D at MedisEl. He holds an MSc. in structural biology and a BSc. in biology from the Hebrew University, a diploma in computer & electronics and has continued his MBA studies at the Hebrew University. He is also a certified Trainer of NLP from ABNLP. (LinkedIn Profile: http://il.linkedin.com/in/tamirhuberman/)
Dr. Reichman is the licensing officer for chemical sciences-based technologies. He brings over 20 years of experience in senior management positions. Dr. Reichman was CEO of Polyheal Ltd., a medical device company and of Patholab Diagnostics Ltd. He is also the founder of a few high tech companies. Dr. Reichman served, in the past, as Sales & Marketing Manager at Sigma-Aldrich (NASDAQ: SIAL) and was the R&D Manager of Adumim Chemicals, a firm based on know-how developed at the Hebrew University, where he was involved in turn-key worldwide projects. Dr. Dov Reichman has a Ph.D. in chemistry from the Hebrew University of Jerusalem.
Mr. Trachtenberg joined Yissum in 2006 as general counsel, and is responsible for all legal aspects of Yissum’s activities, including technology licensing and intellectual property protection. An attorney with over 25 years of experience in the US and Israel, Mr Trachtenberg previously served as general counsel of Keryx Biopharmaceuticals (NASDAQ: KERX) and of Accent Software International He has a J.D. from New York University and a B.A. from the State University of New York at Binghamton.
Ms. Fredman joined Yissum in 2009 as Deputy General Counsel. Prior to joining Yissum, Ms. Fredman served in senior legal positions with several hi-tech and communications companies, including Bezeq International and Starhome (a Comverse affiliate). Ms. Fredman brings to Yissum over 20 years of experience drafting and negotiating complex agreements, managing intellectual property licensing and protection (particularly in the software and communications fields) and advising senior management on a broad range of strategic company issues. Ms. Fredman holds a bachelor of arts degree in economics and in education (Magna Cum Laude; Phi Beta Kappa) from Barnard College (affiliate of Columbia University) and a law degree (L.L.M.) from the Columbia University School of Law. She is a member of the American and Israeli Bar Associations.
Ms. Gallily joined Yissum in 2004 and oversees the professional aspects of Yissum's extensive patent portfolio and provide patent counselling and advice to support business activities. Ms Gallily’s 15 years of professional IP experience prior to joining Yissum include serving as in-house patent counsel at Keryx (NASDAQ: KERX) and as an attorney with a leading intellectual property firm for 15 years, where she focused on drafting and prosecuting patent applications in all fields of the life sciences. Ms Gallily holds an MSc in Physiology (neurobiology) from the Hebrew University and a diploma in organizational counselling from the College of Management.
Ms. Abramzon-Shmueli joined Yissum in 2004 and is responsible for the management and administration of Yissum’s extensive portfolio of intellectual property. The IP department activities include invention disclosures, prosecution of patent applications, inter-institutional agreements and coordinating of outside patent counsel operations.
Prior to joining Yissum, Ms. Abramzon-Shmueli worked at the Jerusalem Municipality’s tax department. She holds a Bachelor’s degree in Philosophy, and a Masters degree in History and Sociology of Science, with expertise in the history of Technology Transfer. Both degrees from the Hebrew University of Jerusalem.
Mr. Baron has over 15 years of management experience at both executive and entrepreneurial levels, with a background in early-stage medical and food-tech companies. Previously, he served as the CEO and co-founder of Ora Bio Ltd and SiL Vascular Ltd, and was the CEO of Bactusense technologies.; Mr. Baron has also worked with Healthcare Ventures, a fund focused on medical technology based companies. Mr. Baron Graduated the "Building Business Bridges' business school of international business at Tel Aviv University. He holds a BSc. in Agriculture from the faculty of agriculture and M.Sc. from the Weizmann institute.